IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, announces that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock (“Common Stock”), plus one non-tradeable contingent value right (“CVR”). The IGM Biosciences Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all IGM Biosciences stockholders and has approved the Merger Agreement and related transactions.
Read the full article: IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right //
Source: https://www.globenewswire.com/news-release/2025/07/01/3108348/0/en/IGM-Biosciences-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-1-247-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html